Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.72 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 8/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31439475 | 0.88 | PDK1 (0.69) | PDK1CASP6TSHRHCAR3LMNA | |
| SCHEMBL30658490 | 0.88 | EP300 (0.61) | PDK1CASP6TSHRHCAR3LMNA | |
| SCHEMBL8800296 | 0.88 | PDK1 (0.72) | PDK1TSHRLMNAXDHALDH1A1 | |
| SCHEMBL528040 | 0.88 | EP300 (0.61) | PDK1CASP6TSHRHCAR3LMNA | |
| SCHEMBL28748723 | 0.87 | PDK1 (0.75) | PDK1TSHRHCAR3LMNAXDH | |
| SCHEMBL6112853 | 0.87 | PDK1 (0.71) | PDK1TSHRLMNAALDH1A1CYP3A4 | |
| SCHEMBL16956345 | 0.86 | PDK1 (0.70) | PDK1TSHRHCAR3LMNAXDH | |
| SCHEMBL28316244 | 0.86 | HCAR3 (0.59) | PDK1CASP6TSHRHCAR3LMNA | |
| SCHEMBL6113956 | 0.85 | PDK1 (0.69) | PDK1TSHRLMNAXDHALDH1A1 | |
| SCHEMBL28317018 | 0.85 | PDK1 (0.69) | PDK1TSHRLMNAALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110183348-B | N- (3-nitro-4-alkoxy benzoyl) amino acid compound, preparation method and application thereof | 中国医科大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-110183348-A | N- (3- nitro -4- alkoxybenzoyl) amino acids, preparation method and its usage | 中国医科大学 | 2019-08-30 | — | — | CN | disclosed |
| EP-2563783-B1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8440698-B2 | 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2563783-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | Allergan, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120302606-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8318783-B2 | 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2011136927-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20110263661-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20070043235-A1 | Process for preparing 3-nitro-4-alkoxybenzoic acid | KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
| CN-1809525-A | Process for producing 3-nitro-4-alkoxybenzoic acid | UENO SEIYAKU OYO KENKYUJO KK (JP) | 2006-07-26 | — | — | CN | disclosed |
| EP-1621528-A1 | PROCESS FOR PRODUCING 3-NITRO-4-ALKOXYBENZOIC ACID | KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | PDK1 1879/4885CASP6 2428/4885TSHR 22/4885 |
| US-20110263661-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR4 | PDK1 1491/4885CASP6 4576/4885TSHR 239/4885 |
| US-20120302606-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR4 | PDK1 1491/4885CASP6 4576/4885TSHR 239/4885 |
| US-20070043235-A1 | Process for preparing 3-nitro-4-alkoxybenzoic acid | NOS3, NOS1, NOS2 | PDK1 2200/4885CASP6 941/4885TSHR 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.